Project Grant R01AI185869
Award Date 8/11/25
Completion Date 7/31/30
Dollars Obligated $697K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $683,927 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai (ISMMS) to develop and characterize broadly neutralizing human monoclonal antibodies (mAbs) as potential therapeutics to inhibit human cytomegalovirus (CMV) infection and dissemination. The key objectives of this 1-year project are to: 1) identify neutralizing CMV mAbs targeting...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $683,995.00 to fund research to develop novel therapeutics targeting human cytomegalovirus (CMV) infections. The research focuses on characterizing the mechanism of action and optimizing a series of N-arylpyrimidinamine (NAPA) compounds that demonstrated potent anti-CMV activity in a high-throughput screening assay....
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $298,582 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, MA. The grant supports the development of novel inhibitors to treat drug-resistant cytomegalovirus (CMV) infections, which are a major cause of morbidity and mortality in immunosuppressed patients, particularly transplant recipients. Microbiotix...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), awarded a $762,983 Project Grant to The Medical College of Wisconsin, Inc. (MCW) to support research focused on "Discovery and Development of Novel HCMV Inhibitors". The goal of this project is to develop a new class of inhibitors that act through a novel viral target, the helicase-primase (H/P) complex, to address the limited...
- The National Institute of Allergy and Infectious Diseases (NIAID), through its Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $1,135,986 Project Grant to Northwestern University. The grant, effective January 1, 2025, aims to identify cellular and molecular targets for developing tissue/cell-specific strategies to prevent cytomegalovirus (CMV) reactivation and improve outcomes in kidney transplant recipients. The research will investigate the role of...
- The Icahn School of Medicine at Mount Sinai was awarded a $6,732,986 Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to study the oral environment and its role in the development of food allergy. The project, titled "The Oral Environment in Food Allergy Development (ONEIDA)", aims to characterize the early-life trajectories of oral mucosal immunology, oral microbial communities, and...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, awarded a $805,375 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai. The grant, awarded on November 20, 2024, supports a 5-year research project to elucidate the cellular tropism, receptor usage, and pathogenesis mechanisms of emerging bat-derived pararubulaviruses, which pose a potential global health...
- This $525,095 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify novel cellular determinants of human cytomegalovirus (HCMV) infection. The University of Rochester, the primary awardee, aims to: Elucidate the mechanisms through which the cellular factor JUNB can restrict HCMV infection. JUNB is a stress-induced transcription factor that regulates...
- The Icahn School of Medicine at Mount Sinai has been awarded a $591,486 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, running from September 1, 2023 to August 31, 2026, will support the development of a novel immuno-oncology pipeline for FGFR2 fusion-positive cholangiocarcinoma. The funding will enable the medical school to conduct research aimed at transforming health care for service members and the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $232,415 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. The goal of this 2-year award, with a period of performance from November 2024 to October 2026, is to develop a highly potent monoclonal antibody that can neutralize the cytomegalovirus (CMV)-encoded interleukin-10 (IL-10) protein, in order to prevent primary CMV infection and reduce the...